Form D · Biotechnology
Alliqua BioMedical, Inc.
Yardley, PA · CIK 0001054274
Offering snapshot reported Mar 13, 2017 · SEC filing
- Reported sold
- $2.77M Offering amount: $2.9M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 27, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 13, 2017 | Initial | $2,770,000 | No comparison | 8 | SEC filing |
| May 15, 2014 | Initial | $2,003,080 | No comparison | 43 | SEC filing |
| Apr 28, 2014 | Initial | $14,975,000 | No comparison | 18 | SEC filing |
| Nov 25, 2013 | Initial | $651,578 | No comparison | 1 | SEC filing |
| Nov 25, 2013 | Initial | $6,000,000 | No comparison | 1 | SEC filing |
| Nov 25, 2013 | Initial | $7,000,000 | No comparison | 12 | SEC filing |
| Nov 18, 2013 | Amendment | $1,000,000 | $0vs Nov 6, 2013 | 1 | SEC filing |
| Nov 6, 2013 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Jul 9, 2013 | Initial | $1,976,925 | No comparison | 30 | SEC filing |
| Jun 10, 2013 | Amendment | $1,100,000 | $288,000vs May 7, 2013 | 26 | SEC filing |
| May 7, 2013 | Amendment | $812,000 | $110,000vs Apr 24, 2013 | 19 | SEC filing |
| Apr 24, 2013 | Amendment | $702,000 | $466,000vs Apr 18, 2013 | 17 | SEC filing |
| Apr 18, 2013 | Initial | $236,000 | No comparison | 8 | SEC filing |
| Nov 15, 2012 | Initial | $815,000 | No comparison | 10 | SEC filing |
| Aug 29, 2012 | Initial | $265,000 | No comparison | 4 | SEC filing |
| Mar 1, 2012 | Initial | $1,050,000 | No comparison | 12 | SEC filing |
| Mar 17, 2011 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| May 25, 2010 | Initial | $10,600,000 | No comparison | 17 | SEC filing |
| May 25, 2010 | Initial | $1,425,000 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $196K
- Finders' fees
- $0
- Form D file number
- 021-282404
$161,980 was paid to Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC. $34,200 was paid to Cova Capital Partners, LLC.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Rodman & Renshaw, LLC | 281264 | H.C. Wainwright & Co., LLC · CRD 375 |
| Cova Capital Partners, LLC | 109761 |
Source: Form D, filed Mar 13, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brad Barton | Executive |
| Steven Berger | Executive |
| Michael Goldberg | Director |
| David Johnson | Director, Executive |
| Perry Karsen | Director |
| Winston Kung | Director |
| Joseph Leone | Director |
| Kenneth Londoner | Director |
| Kenneth Pearsen | Director |
| Pellegrino Pionati | Executive |
| Brian Posner | Executive |
| Gary Restani | Director |
| Richard Rosenblum | Director |
| James Sapirstein | Director, Executive |
| Joseph Sierchio | Director |
| Jeffrey Sklar | Director |
| David Stefansky | Director |
| Nochum Stein | Director |
| Mark Wagner | Director |
| Jerome Zeldis | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1010 Stony Hill Road Suite 200
Yardley, PA, 19067
Yardley, PA, 19067